Neuroone Medical Ownership
| NMTC Stock | USD 0.76 0.02 2.70% |
Shares in Circulation | First Issued 2010-06-30 | Previous Quarter 27.4 M | Current Value 27.1 M | Avarage Shares Outstanding 6.9 M | Quarterly Volatility 7.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Neuroone |
Neuroone Stock Ownership Analysis
About 16.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.46. Neuroone Medical Tec had not issued any dividends in recent years. The entity had 1:3 split on the 1st of April 2021. NeuroOne Medical Technologies Corporation operates as a medical technology company. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOnes combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. Neuroone Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. To find out more about Neuroone Medical Technologies contact David MD at 952 426 1383 or learn more at https://www.n1mtc.com.Besides selling stocks to institutional investors, Neuroone Medical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Neuroone Medical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Neuroone Medical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Neuroone Medical Quarterly Liabilities And Stockholders Equity |
|
About 16.0% of Neuroone Medical Technologies are currently held by insiders. Unlike Neuroone Medical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Neuroone Medical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Neuroone Medical's insider trades
Neuroone Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuroone Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuroone Medical Technologies backward and forwards among themselves. Neuroone Medical's institutional investor refers to the entity that pools money to purchase Neuroone Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aurum Wealth Management Group Llc | 2024-09-30 | 12 K | Tower Research Capital Llc | 2024-09-30 | 4.3 K | Advisor Group Holdings, Inc. | 2024-09-30 | 1.3 K | Simplex Trading, Llc | 2024-09-30 | 1 K | Wells Fargo & Co | 2024-09-30 | 333 | Bank Of America Corp | 2024-09-30 | 229 | Ubs Group Ag | 2024-09-30 | 108 | Jpmorgan Chase & Co | 2024-09-30 | 69.0 | Centerpoint Advisors, Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 919.5 K | Nantahala Capital Management, Llc | 2024-09-30 | 798.8 K |
Neuroone Medical Tec Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuroone Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuroone Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuroone Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuroone Medical Outstanding Bonds
Neuroone Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuroone Medical Tec uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuroone bonds can be classified according to their maturity, which is the date when Neuroone Medical Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.158 | Quarterly Revenue Growth 0.311 | Return On Assets (1.43) | Return On Equity (3.49) |
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.